An Inhibitor of the δPKC Interaction with the d Subunit of F1Fo ATP Synthase Reduces Cardiac Troponin I Release from Ischemic Rat Hearts: Utility of a Novel Ammonium Sulfate Precipitation Technique

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ogbi, Mourad ^a   Obi, Ijeoma ^a   Johnson, John A ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM SULFATE; CHLOROFORM; ENZYME INHIBITOR; F1F0 ADENOSINE TRIPHOSPHATE SYNTHASE D SUBUNIT; METHANOL; POLYPEPTIDE; PROTEIN KINASE C DELTA; PROTEIN KINASE C DELTA F1F0 ADENOSINE TRIPHOSPHATE SYNTHASE D SUBUNIT INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SOYBEAN TRYPSIN INHIBITOR; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; ISOLATED HEART; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRECIPITATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RAT; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AMMONIUM SULFATE; ANIMALS; BIOLOGICAL MARKERS; CHEMICAL PRECIPITATION; CHLOROFORM; MALE; METHANOL; MITOCHONDRIAL MEMBRANES; MOLECULAR SEQUENCE DATA; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PEPTIDES; PERFUSION; PROTEIN BINDING; PROTEIN KINASE C-DELTA; PROTEIN SUBUNITS; PROTON-TRANSLOCATING ATPASES; RATS; RATS, SPRAGUE-DAWLEY; SOYBEANS; TROPONIN I; TRYPSIN INHIBITORS;

EID: 84881021198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070580     Document Type: Article

References (51)

1. Murphy E, Steenbergen C, (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-609.
2. Solaini G, Harris DA, (2005) Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J 390: 377-394.
3. Fredericks S, Mertona GK, Lerena MJ, Heining P, (2001) Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clinica Chimica Acta 304: 65-74.
4. Applel FS, Collinson, PO (2012) for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clinical Chemistry 58: 54-61, 2012.
5. Christenson RH, Phillips D, (2011) Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name. Pathology 43: 213-219.
6. Vogt AM, Elsasser A, Pott-Beckert A, Ackermann C, Vetter SY, et al. (2005) Myocardial energy metabolism in ischemic preconditioning and cardioplegia: a metabolic control analysis. Mol Cell Biochem 278: 223-232.
7. Bers DM, (2002) Cardiac excitation-contraction coupling. Nature 415: 198-205.
8. Palmer BS, Klawitter PF, Reiser PJ, Angelos MG, (2004) Degradation of rat cardiac troponin I during ischemia independent of reperfusion. Am J Physiol Heart Circ Physiol 287: H1269-H1275.
9. Baines CP, Song C, Zheng Y, Wang G, Zhang J, et al. (2003) Protein kinase Cε interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92: 873-880.
10. Costa ADT, Garlid KD, West IC, Lincoln TM, Downey JM, et al. (2005) Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329-336.
11. Inagaki K, Churchill E, Mochly-Rosen D, (2006) Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 70: 222-230.
12. Liang BT, (1997) Protein kinase C-mediated preconditioning of cardiac myocytes: role of adenosine receptor and KATP channel. Am J Physiol Heart Cir. Physiol 273: H847-H853.
13. Meldrum DR, (1997) Mechanisms of cardiac preconditioning ten years after the discovery of ischemic preconditioning. J Surg Res 73: 1-13.
14. Nguyen T, Ogbi M, Johnson JA, (2008) Delta protein kinase C interacts with the d subunit of the F1Fo ATPase in neonatal cardiac myocytes exposed to hypoxia or phorbol ester: Implications for F1Fo ATPase regulation. J Biol Chem 283: 29831-29840.
15. Nguyen T, Yu Q, Ogbi M, Johnson JA, (2010) Modulation of the δPKC interaction with the "d" subunit of F1F0 ATP synthase in neonatal cardiac myocytes: Development of cell-permeable, mitochondrial-targeted inhibitor and facilitator peptides. J Biol Chem 285: 22164-22173.
16. Nguyen T, Ogbi M, Yu Q, Johnson JA, (2010) Attenuation of the hypoxia-induced protein kinase Cδ interaction with the "d" subunit of F1F0 ATP synthase in neonatal cardiac myocytes: implications for energy preservation and survival. Biochem J 429: 335-345.
17. Nguyen T, Ogbi MO, Guo D, Johnson JA, (2007) Modulation of mitochondrial protein kinase C isozymes: a new therapeutic frontier? Curr Enz Inhibition 3: 143-159.
18. Inagaki K, Hahn HS, Dorn II GW, Mochly-Rosen D, (2003) Additive protection of the ischemic heart ex-vivo by combined treatment with δ protein kinase C inhibitor and ε protein kinase C activator. Circulation 108: 869-875.
19. Guo D, Nguyen T, Ogbi M, Tawfik H, Ma G, et al. (2007) Protein kinase C-ε, with cytochrome oxidase subunit IV and is associated with improved cytochrome-c oxidase activity and cardioprotection. Am J Physiol Heart Circ Physiol 293: H2219-H2230.
20. Ogbi M, Chew CS, Pohl J, Stuchlik O, Ogbi S, et al. (2004) Cytochrome c oxidase subunit IV as a marker of protein kinase Cε function in neonatal cardiac myocytes: implications for cytochrome c oxidase activity. Biochem J 382, 1-10.
21. Ogbi M, Johnson JA, (2006) Protein kinase Cε interacts with cytochrome c oxidase subunit IV and enhances cytochrome c oxidase activity in neonatal cardiac myocyte preconditioning. Biochem J 393: 191-199.
22. Yu Q, Nguyen T, Ogbi M, Caldwell RW, Johnson JA, (2008) Differential loss of cytochrome-c oxidase subunits in ischemia reperfusion injury: exacerbation of COI subunit loss by PKC-ε inhibition. Am J Physiol Heart Circ Physiol 294: H2637-H2645.
23. Johnson JA, Ogbi M, (2011) Targeting the F1Fo ATP synthase: modulation of the body's powerhouse and its implications for human disease. Curr Med Chem 18: 4684-4714.
24. Takeo S, Nasa Y, (1999) Role of energy metabolism in the preconditioned heart: a possible contribution of mitochondria. Cardiovasc Res 43: 32-43.
25. Vuorine K, Ylitalo K, Peuhkurinen K, Raatikainen P, Ala-Rami A, et al. (1995) Mechanisms of ischemic preconditioning in rat myocardium: roles of adenosine, cellular energy state, and mitochondrial F1Fo-ATPase. Circulation 91: 2810-2818.
26. Budas GR, Churchill EN, Disatnik M-H, Sun L, Mochly-Rosen D, (2010) Mitochondrial import of PKCε is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury. Cardiovasc Res 88: 83-92.
27. Smith RM and Jarret L (1993) Electron microscopic immunohistochemical approaches to the localization of ligands, receptors, tranducers and transporters. In Handbook of Endocrine Research Techniques, F de Pablo, CG Scanes and BD Weintraub, eds, Academic Press, San Diego, CA, 227-263.
28. Slot JW, Geuze HJ, (1985) A new method of preparing gold probes for multiple labeling cytochemistry. Eur J Cell Biol 38: 87-93.
29. Horisberger M, (1979) Evaluation of colloidal gold as a cytochemical marker for transmission and scanning electron microscopy. Biol Cell 36: 253-258.
30. McDonough JL, Arrell DK, Van Eyk JE, (1999) Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res 84: 9-20.
31. Hitchcock SE, Zimmerman CJ, Smalley C (1981) Study of the structure of troponin-T by measuring the relative reactivities of lysines with acetic anhydride. J Mol Biol 147, 125-151.
32. Jaquet NBK, Schnackerz K, Heilmeyer LMG, (1988) Isolation and characterization of a highly phosphorylated troponin from bovine heart. Eur J Biochem 176: 327-334.
33. Twerenbolda R, Reichlina T, Reitera M, Muellera C, (2011) High-sensitive cardiac troponin: friend or foe? Swiss Med Wkly 141: w13202.
34. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
35. Lemire BD, Fankhauser C, Baker A, Schatz G, (1989) The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity. J Biol Chem 264: 20206-20215.
36. Tate JR, Bunk DM, Christenson RH, Katrukhac A, Noble JE, et al. (2010) For The IFCC Working Group on Standardization of Troponin. Standardization of cardiac troponin I measurement: past and present. Pathology 42: 402-408.
37. Bi SH, Jin ZX, Zhang JY, Chen T, Zhang SL, et al. (2012) Calpain inhibitor MDL 28170 protects against the Ca2+ paradox in rat hearts. Clin Exp Pharmacol Physiol 39: 385-92.
38. Ferrera R, Bopassa J-C, Angoulvant D, Ovize M, (2007) Post-conditioning Protects From Cardioplegia and Cold Ischemia via Inhibition of Mitochondrial Permeability Transition Pore. J Heart Lung Transplant 26: 604-609.
39. Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA, (2010) Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. J Mol Cell Cardiol 49: 886-93.
40. Riess ML, Camara AKS, Chen O, Novalija E, Rhodes SS, et al. (2002) Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts. Am J Physiol Heart Circ Physiol 283: H53-H60.
41. Sigg DC, Coles JA Jr, Gallagher WJ, Oeltgen PR, Iaizzo PA, (2001) Opioid Preconditioning: Myocardial Function and Energy Metabolism. Ann Thorac Surg 72: 1576-82.
42. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE, (2000) Extensive troponin I and troponin T modification detected in serum from patients with acute myocardial infarction. Circulation 102: 1221-1226.
43. McDonough JL, Labugger R, Pickett W, Tse MY, MacKenzie S, et al. (2001) Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 103: 58-64.
44. Shi Q, Ling M, Zhang X, Zhang M, Kadijevic L, et al. (1999) Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clinical Chem 45: 1018-1025.
45. Li T, Zhu D, Zhou R, Wu W, Li Q, et al. (2012) HBOC attenuates intense exercise-induced cardiac dysfunction. Int J Sports Med 33: 338-45.
46. Afonso L, Bandaru H, Rathod A, Badheka A, Kizilbash MA, et.al (2011) Prevalence, determinants, and clinical significance of cardiac troponin-I elevation in individuals admitted for a hypertensive emergency. J Clin Hypertens (Greenwich) 13: 551-556, 2011.
47. Bozcali E, Dedeoglu DB, Karpuz V, Suzer O, Karpuz H, (2012) Cardioprotective effects of zofenopril, enalapril, and valsartan against ischemia/reperfusion injury as well as doxorubicin cardiotoxicity. Acta Cardiol 67: 87-96.
48. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, et al. (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107: 1375-1380.
49. Bertinchant J-P, Robert E, Polge A, de la Coussaye J-E, Pignodel C, et al. (1999) Release kinetics of cardiac troponin I and cardiac troponin T in effluents from isolated perfused rabbit hearts after graded experimental myocardial contusion. J Trauma Injury Infect & Crit Care. 47: 474-480.
50. O'Brien PJ, Smith DEC, Knechtel TJ, Marchak MA, Pruimboom-Brees I, et al. (2006) Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Laboratory Animals 40: 153-171.
51. Serra M, Papakonstantinou S, Adamcova M, O'Brien PJ, (2010) Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin. The Veterinary Journal 185: 50-57.